BSI 500
Alternative Names: BSI-500Latest Information Update: 04 Oct 2022
Price :
$50 *
At a glance
- Originator Biosion; Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Sep 2022 Preclinical trials in Solid tumours in China (Parenteral) (Biosion pipeline, September 2022)
- 12 Sep 2022 Chia Tai Tianqing Pharmaceutical plans to file an IND application for Solid tumours in the second half of 2023 (Biosion pipeline, September 2022)
- 30 Nov 2021 Biosion and Chia Tai Tianqing Pharmaceutical Group (CTTQ) enters into a collaborative agreement for the development and commericalisation of BSI 500 before November 2021 (Biosion pipeline, September 2022)